Article
Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study.
Scientific reports - 6 Jun 2017
Palladino Claudia, Sánchez-Carrillo Marta, Mate-Cano Irene, Vázquez-Morón Sonia, Jimenez-Sousa Ma Ángeles, Gutiérrez-Rivas Mónica, Resino Salvador, Briz Verónica
Abstract excerpt
Relevant resistance-associated substitutions (RASs) to elbasvir, the new HCV NS5A inhibitor, may limit its efficacy and lead to virological failure in HCV-GT1a-infected patients. There are few data outside clinical trials evaluating their prevalence and impact of elbasvir/grazoprevir. A multicenter cross-sectional study of 617 HCV-GT1a-infected individuals attended in 84 Spanish hospitals from the 17 Autonomous...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
